欢迎访问《现代生物医学进展》编辑部！

类风湿性关节炎是常见的自身免疫性疾病，可引起关节肿痛、畸形以及不同程度的残疾，影响了患者的生活质量。随着对发病机制的深入研究，出现了越来越多的治疗类风湿性关节炎的药物，依据发展的时间及原理，共分为五代：第一代是非甾体类抗炎药物；第二代是糖皮质激素；第三代是改变病情药（慢作用抗风湿药）；第四代是以 α 肿瘤坏死因子（ TNF-α ）抑制剂为主的早期生物制剂；第五代为直接针对 T 细胞发生作用的新型生物制剂。其中第四代和第五代的生物制剂是近年来治疗类风湿性关节炎的新型药物，与传统药物相比体现了明显的优势，具有广泛的应用前景。本文对类风湿性关节炎的发病机制进行简要阐述，重点对类风湿性关节炎治疗药物的新进展进行综述。

英文摘要:

Rheumatoid arthritis is a common autoimmune disease, can cause joint pain, deformity and disability to varying degrees, and affects the patient's quality of life. Along with the in-depth study of the pathogenesis, there have been a growing number of rheumatoid arthritis drugs. Based on the time of development and principle, is divided into five generation: the first generation is nonsteroidal antiinflammatory drugs (NSAIDs), the second generation is glucocorticoid, the third generation is disease modifying anti-rheumatic drugs (DMARDs), also known as slow acting anti-rheumatic drugs (SAARDs), the fourth generation is early biological agents such as TNF-琢, the fifth generation is new biological agents, which specific effect on T lymphocytes. Biological agents are novel drugs for the treatment of rheumatoid arthritis in recent years, which reflect a clear advantage compared with traditional medicines and have broad application prospects. This review describes the pathogenesis of rheumatoid arthritis briefly and focuses on the therapeutic drugs.

查看全文查看/发表评论下载PDF阅读器

关闭